P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)

Detalles Bibliográficos
Autores principales: Sehn, L. H., Hübel, K., Luminari, S., Salar, A., Wahlin, B. E., Gopal, A. K., Bonnet, C., Paneesha, S., Trneny, M., Mashegu, H., Lihou, C., Li, D., Scholz, C. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429088/
http://dx.doi.org/10.1097/01.HS9.0000847280.69256.81
_version_ 1784779325269082112
author Sehn, L. H.
Hübel, K.
Luminari, S.
Salar, A.
Wahlin, B. E.
Gopal, A. K.
Bonnet, C.
Paneesha, S.
Trneny, M.
Mashegu, H.
Lihou, C.
Li, D.
Scholz, C. W.
author_facet Sehn, L. H.
Hübel, K.
Luminari, S.
Salar, A.
Wahlin, B. E.
Gopal, A. K.
Bonnet, C.
Paneesha, S.
Trneny, M.
Mashegu, H.
Lihou, C.
Li, D.
Scholz, C. W.
author_sort Sehn, L. H.
collection PubMed
description
format Online
Article
Text
id pubmed-9429088
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94290882022-08-31 P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL) Sehn, L. H. Hübel, K. Luminari, S. Salar, A. Wahlin, B. E. Gopal, A. K. Bonnet, C. Paneesha, S. Trneny, M. Mashegu, H. Lihou, C. Li, D. Scholz, C. W. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429088/ http://dx.doi.org/10.1097/01.HS9.0000847280.69256.81 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Sehn, L. H.
Hübel, K.
Luminari, S.
Salar, A.
Wahlin, B. E.
Gopal, A. K.
Bonnet, C.
Paneesha, S.
Trneny, M.
Mashegu, H.
Lihou, C.
Li, D.
Scholz, C. W.
P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
title P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
title_full P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
title_fullStr P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
title_full_unstemmed P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
title_short P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
title_sort p1103: inmind: a phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma (fl) or marginal zone lymphoma (mzl)
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429088/
http://dx.doi.org/10.1097/01.HS9.0000847280.69256.81
work_keys_str_mv AT sehnlh p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl
AT hubelk p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl
AT luminaris p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl
AT salara p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl
AT wahlinbe p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl
AT gopalak p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl
AT bonnetc p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl
AT paneeshas p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl
AT trnenym p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl
AT masheguh p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl
AT lihouc p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl
AT lid p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl
AT scholzcw p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl

Ejemplares similares